Loughnan M S, Heriot W J, O'Day J
Melbourne University, Department of Ophthalmology, Victoria, Australia.
Aust N Z J Ophthalmol. 1992 Aug;20(3):173-5. doi: 10.1111/j.1442-9071.1992.tb00936.x.
Systemic interferon-alpha has recently been reported to be useful in the treatment of choroidal neovascular membranes (CNVM) in age-related macular degeneration. To further investigate its effect we treated eight patients with subfoveal choroidal neovascular membranes of various aetiologies including idiopathic, age-related macular degeneration and myopic chorioretinal degeneration. Only one of the eight patients responded with an angiographically demonstrated decrease in the size of the CNVM; this was in a patient from the idiopathic group. Considerable side-effects were reported with marked lethargy and malaise limiting compliance with some patients. Although this is an initial report with limited patient numbers and follow-up, it does suggest a role for interferon-alpha in patients with idiopathic neovascular membranes where the retina is otherwise normal, but raises some doubt as to its efficacy in the treatment of age-related macular degeneration.
最近有报道称，全身应用干扰素-α 可有效治疗年龄相关性黄斑变性中的脉络膜新生血管膜（CNVM）。为了进一步研究其疗效，我们对8例患有不同病因的黄斑下脉络膜新生血管膜的患者进行了治疗，这些病因包括特发性、年龄相关性黄斑变性和近视性脉络膜视网膜变性。8例患者中只有1例在血管造影中显示CNVM大小减小，该患者来自特发性组。据报道，有相当多的副作用，表现为明显的嗜睡和不适，限制了一些患者的依从性。尽管这是一份患者数量有限且随访时间有限的初步报告，但它确实表明干扰素-α 在视网膜其他方面正常的特发性新生血管膜患者中具有一定作用，但对其在年龄相关性黄斑变性治疗中的疗效提出了一些疑问。
